News
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3b AVA-PED-301 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback